A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Brief description of study
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination of drugs. Investigational means that the drug or the combination of drugs is still being studied and that research doctors are trying to find out more. It also means that the US Food and Drug Administration (FDA) or any Health Authority has not approved CC-220 alone or in combination with other treatments for use in patients, including people with your type of disease (multiple myeloma).
Clinical Study Identifier: s19-00817
ClinicalTrials.gov Identifier: NCT02773030
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
